Valneva SE (VALN) Total Non-Current Liabilities (2020 - 2026)

Valneva SE's (VALN) quarterly Total Non-Current Liabilities came in at $235.4 million in Q1 2026, up 11.47% year-on-year from $211.2 million in Q1 2025, and up 1.46% quarter-over-quarter from $232.0 million in Q4 2025.

Valneva SE (VALN) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends

Valneva SE has disclosed Total Non-Current Liabilities across 7 years of filings, most recently posting $235.4 million for Q1 2026.

  • Total Non-Current Liabilities for Q1 2026 came in at $235.4 million, up 11.47% year-over-year; the trailing twelve-month figure through Mar 2026 was $235.4 million (up 11.47% YoY), and the FY2025 annual result was $232.0 million, up 6.34% from the prior year.
  • Total Non-Current Liabilities came in at $235.4 million for Q1 2026 at Valneva SE, up from $232.0 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $298.6 million in Q1 2022 to a low of $120.7 million in Q2 2023.
  • The 5-year median for Total Non-Current Liabilities is $208.6 million (2024), against an average of $192.7 million.
  • Across the five-year window, Total Non-Current Liabilities tumbled 60.14% in 2022 and surged 76.52% in 2024, its largest moves.
  • Valneva SE's Total Non-Current Liabilities stood at $126.7 million in 2022, then surged by 46.91% to $186.1 million in 2023, then increased by 17.26% to $218.2 million in 2024, then rose by 6.34% to $232.0 million in 2025, then grew by 1.46% to $235.4 million in 2026.
  • The last three Total Non-Current Liabilities figures came in at $235.4 million (Q1 2026), $232.0 million (Q4 2025), and $172.2 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Alterity Therapeutics 723,416.35 Bn 723,416.32 Bn - 42,980.09
2 Belite Bio 57,340.00 Bn 57,340.00 Bn - -
3 Quantum Biopharma 19,125.08 Bn 19,125.08 Bn - 11.03 Mn
4 Legend Biotech 3,262.00 Bn 3,261.71 Bn 242.10 Mn 95.20 Mn
5 Akari Therapeutics 1,789.67 Bn 1,789.67 Bn - -
6 Evaxion A 1,480.39 Bn 1,480.37 Bn - -
7 Psyence Biomedical 241.78 Bn 241.78 Bn - 644,700.00
8 Vertex Pharmaceuticals 113.54 Bn 106.29 Bn 2.59 Bn 5.87 Bn
9 Abivax 94.26 Bn 94.26 Bn - 64.76 Mn
10 Valneva SE 167.33 Mn 44.10 Mn 5.08 Mn 235.43 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 235.43 Mn
Dec 31, 2025 232.03 Mn
Sep 30, 2025 172.17 Mn
Jun 30, 2025 181.72 Mn
Mar 31, 2025 211.21 Mn
Dec 31, 2024 218.21 Mn
Sep 30, 2024 208.65 Mn
Jun 30, 2024 213.01 Mn
Mar 31, 2024 214.57 Mn
Dec 31, 2023 186.09 Mn
Sep 30, 2023 157.70 Mn
Jun 30, 2023 120.68 Mn
Mar 31, 2023 130.90 Mn
Dec 31, 2022 126.67 Mn
Sep 30, 2022 160.20 Mn
Jun 30, 2022 208.85 Mn
Mar 31, 2022 298.60 Mn
Dec 31, 2021 317.78 Mn
Dec 31, 2020 233.54 Mn